



# Committee Application Form

Town of Natick  
Board of Selectmen / Town Administrator  
13 East Central Street  
Natick, MA 01760  
(508) 647-6410

**Thank you for your interest in serving the Town of Natick.** Please use this form for appointments made by the Board of Selectmen or the Town Administrator. You may also provide a letter and/or resumé. After we receive your application, you will be contacted regarding next steps.

**Position applied for:** Leonard Morse Grants Panel for Metro West Health Foundation

Please check if this is a ☐ new appointment or ☒ reappointment

**Name:** Virginia Seery

**Address:** 34 Forest Ave., Natick, MA 01760

**Phone:** 508 733 4312

**Email (optional):** vseery@gmail.com

**Relevant experience:** I have served two previous terms on the Leonard Morse Grants panel and

hope to serve one more. I have been a nurse practitioner for over twenty-five years, most of that

in the oncology field. I feel I bring a unique perspective to the panel and very much enjoy volunteering

in this role to give back to the Metrowest area.

**Relevant education:** Master of Science in Nursing, Yale University 1991

Bachelor of Science in Nursing, University of Maine at Orono 1986

Please check if you... ☒ are familiar with the State Ethics Law

☐ have attended a State Ethics Law seminar

Please check if you are enclosing a ☐ letter and/or a ☒ resumé

**Signature:** Virginia Seery

*Send to Board of Selectmen, 13 East Central Street, Natick MA 01760; fax (508) 647-6401*

**Virginia J. Seery, MSN, RN, ANP-BC**

Beth Israel Deaconess Medical Center  
330 Brookline Avenue  
Boston, MA 02215

**PROFESSIONAL EXPERIENCE**

**Beth Israel Deaconess Medical Center, Boston, MA**

11/03 – present

**Adult Nurse Practitioner, Biologics and Cutaneous Oncology Programs**

- Manage inpatient melanoma and renal cell carcinoma population receiving high dose IL-2 therapy and biochemotherapy
- Assess, diagnose and treat individuals with melanoma in the multidisciplinary cutaneous oncology program
- Provide care for outpatient population with metastatic melanoma and metastatic renal cell carcinoma, including clinical trials
- Precept nurse practitioner students

**Youville Hospital and Rehabilitation Center, Cambridge, MA**

8/93-10/03

**Nurse Practitioner Program Coordinator**

- Manage and train nurse practitioners on medical staff
- Coordinate clinical coverage for inpatient units
- Significantly expanded nurse practitioner program
- Liaison for clinical departments
- Member of management team

**Adult Nurse Practitioner, Oncology and Neurology Units**

- Assess, diagnose and treat oncology and neurology population with multiple medical problems
- Lead multidisciplinary team in management of clients with complex medical, nursing, rehabilitation and psychosocial needs
- Coordinate rehabilitation care with primary care team
- Chairperson for hospital-wide pain management committee
- Preceptor for nurse practitioner and physician assistant students
- Credentialed medical staff member of Youville Hospital and Spaulding Rehabilitation Center

**Beth Israel Hospital, Boston, MA**

9/86-8/93

**Primary Nurse, Collaborative Care Medical-Surgical, Neurology and Cardiothoracic Units**

- Cared for patients with intensive nursing needs
- Assisted in the development of a nurse/physician collaboration model
- Coordinated medical student seminar on nursing and collaboration

**Yale New Haven Hospital, New Haven, CT**

9/89-5/91

**Registered Nurse, Cardiothoracic Surgical Step-down Unit**

- Provided postoperative nursing care for patients undergoing coronary artery bypass, valve and thoracic surgery, and heart/lung transplantation

## EDUCATION

**Yale University School of Nursing, New Haven, CT**  
**Master of Science in Nursing with Honors, May 1991**

- Concentration in Medical-Surgical Nursing, Surgical Clinical Nurse Specialist Tract
- Subspecialty in Adult Nurse Practitioner Program
- President, Student Government Organization

**University of Maine at Orono, Orono, ME**  
**Bachelor of Science in Nursing, Summa Cum Laude, May 1986**

## CERTIFICATIONS

- American Nurses Credentialing Center/Board Certification, Adult Nurse Practitioner, 12/91-present
- Advanced Cardiac Life Support, 2/94-present

## PUBLICATIONS

- V. Seery. Interprofessional collaboration with immune checkpoint inhibitor therapy: the roles of gastroenterology, endocrinology and neurology. *Seminars in Oncology Nursing*. 2017 November;33:4: 402-414.
- V. Seery. Intralesional therapy: Consensus statements for best practices in administration from the Melanoma Nursing Initiative. *Clin J Oncol Nurs*. 2017 Aug; 1;21(4 Suppl):76-86.
- B. I. Rini, D. F. McDermott, H. Hammers, W. Bro, R. M. Bukowski, B. Faba, J. Faba, R. A. Figlin, T. Hutson, E. Jonasch, R. W. Joseph, B. C. Leibovich, T. Olencki, A. J. Pantuck, D. I. Quinn, V. Seery, M. H. Voss, C. G. Wood, L. S. Wood, M. B. Atkins. Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. *Journal for ImmunoTherapy of Cancer*. 2016;4:81: 1-15.
- D. E. Peterson, J. A. O'Shaughnessy, H. S. Rugo, S. Elad, M. M. Schubert, C. T. Viet, C. Campbell-Baird, J. Hronek, V. Seery, J. Divers, J. Glaspy, B. L. Schmidt, T. F. Meiller. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. *Cancer Med*. 2016 Aug;5(8):1897-1907.
- Kim, C. C., Najita, J.S., Tan, S.Y., Varada, S., Tong, L. X., Dunbar, H., Lee, M., Seery, V. J., Buchbinder, E. I., Tawa, N. E., Fuller, J., Frankenthaler, R. A., McDermott, D. F., Lee, S. J., Atkins, M. B. Factors associated with worse outcome for patients with AJCC stage IIC related to stage IIIA melanoma. *Journal of Clinical Oncology*. 2015; 33:15 \_suppl, 9078-9078.
- Mahoney, K., Harshman, L. C., Seery, V., Drake, C. G. Immune checkpoint inhibition in renal cell carcinoma. In Lara, P, Jonasch, E, eds. *Kidney Cancer: Principles and Practice*. 2<sup>nd</sup> ed. Springer: 2015: 259-279.
- Y. Xing, C. Hu, M. Lee, V. Seery, C. C. Kim, N. Tawa, R. Frankenthaler, D.F. McDermott, E. I. Buchbinder. Association between mitotic rate and lymph node metastasis in thin melanoma in the general population. *Journal of Clinical Oncology*. 2014; 32:15. (suppl, e20039).
- E. R. DeRose, A. Pleet, V. J. Seery, M. Lee, S. Renzi, R. J. Sullivan, M. B. Atkins. Utility of 3-year torso CT and head imaging in asymptomatic patients with high risk melanoma. *Melanoma Research*. 2011. Aug; 21(4): 364-369.

- V. J. Seery, B. M. McGree, M. Lee, D. F. McDermott, D. C. Cho. Patient reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC). *Journal of Clinical Oncology*. 28:15s, 2010 (suppl; abstr 9051).
- R. J. Sullivan, A. Frankenthaler, W. Wang, V. J. Seery, M. Lee, H. B. Koon, M. B. Atkins. A retrospective comparison of twelve weeks versus fifty two weeks of adjuvant interferon for patients with stage IIb, IIc, and IIIA (IIB-IIIa). *Journal of Clinical Oncology*. 28, 2010 (suppl; abstr e19013).
- A. Frankenthaler, R. J. Sullivan, W. Wang, S. Renzi, V. Seery, M. Lee, M. B. Atkins. Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. *Melanoma Research*. 2010. Dec; 20(6): 496-500.
- Cho DC, Puzanov I, Regan MM, Schwarzbarg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. *Journal of Immunotherapy*. 2009 Feb-Mar;32(2):181-5.
- T. Schwarzbarg, M. M. Regan, V. Liu, J. W. Mier, H. Koon, R. S. Bhatt, V. Seery, K. Bradley, M. B. Atkins, D. F. McDermott. Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. *Journal of Clinical Oncology*. 2008; 26(15)\_suppl 5044.
- Van Dervliet HJ, Koon HB, Yue SC, Uzunpamuk B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley, MA. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. *Clin Cancer Res*. 2007 Apr 1; 13 (7):2100-8.
- Gallagher, DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. *Clin Cancer Res*. 2007 Apr 1; 13(7):2115-20.
- "Daily Hassles of Married Women With Children: An Empirical Foundation For a Preventive Program," Co-authored with S. McCowry, RN, FAAN, PhD, et al., *Journal of the American Psychiatric Nurses Association*, Volume 6, No. 4, 2000, pp. 107-111.

## PRESENTATIONS

- "Interleukin-2 Toxicity and Its Management", Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada, September 2005
- "High Dose Interleukin-2 Toxicity and Its Management", Nursing Grand Rounds, Cross Cancer Institute, Edmonton, Alberta, Canada, March 2, 2006
- "High Dose Interleukin-2 Toxicity and Its Management", Canadian Melanoma Conference, Banff, Alberta, Canada, March 4, 2006
- "High Dose Interleukin-2 Toxicity and Its Management", Novartis Preceptorship Workshop, Boston, MA, May 2, 2006
- "Panel Discussion - Side Effect Management of Treatment for Metastatic RCC", Annual Patient Symposium – 2007-present
- "High Dose Interleukin-2 Toxicity and Its Management", Boston Oncology Nursing Society, April 2008
- "Toxicity Management of Targeted Therapy and Immunotherapy for Melanoma", Mary Mulready Sullivan Oncology Symposium, Hartford Hospital, Hartford, CT, May 15, 2013
- "Oncology Grand Rounds: Nursing and Physician Investigators Discuss New Agents and Novel Therapies Related to Actual Cases from Practice" by Research to Practice, An 8-Part CNE Symposia Series Held During the 41<sup>st</sup> Annual ONS Congress, San Antonio, TX, April 27, 2016
- "Managing Side Effects of Immunotherapy" for ION Solutions, New Orleans, LA, September 2016
- Organizer, Advances in Cancer Immunotherapy, Society for Immunotherapy of Cancer, Boston, MA, September 8, 2016

- "The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials Workshop", Ancillary Satellite Symposium Held Adjunct to The Oncology Nursing Society Annual Meeting by Physicians' Education Resource, LLC, Denver, CO, May 7, 2017
- Immunotherapy for Oncology, Nursing Grand Rounds, BIDMC, Boston, MA, September 20, 2017
- "Nursing Perspective on irAE's: Patient Education, Monitoring and Management, Advances in Cancer Immunotherapy, Society for Immunotherapy of Cancer, Boston, MA, October 5, 2017
- Cancer Immunotherapy Today and Tomorrow, Cancer Center, BIDMC, Boston, MA, October 28, 2017
- "Treatment Modalities: Immune Therapy – Melanoma Case Study" OCN Review Course for Boston Oncology Nursing Society, Lahey Hospital, Burlington, MA, April 2018
- "Oncology Nurse View: Immune Checkpoint Inhibitors in Genitourinary Cancers" held in conjunction with ONS Congress, Washington, DC, May 19, 2018
- "Practical Barriers in Cancer Immunotherapy Treatment", Advances in Cancer Immunotherapy, Society for Immunotherapy of Cancer, Boston, MA, September, 27, 2018

## **MEMBER**

- Melanoma Nursing Initiative, Board Member, 2017-present
- Kidney Cancer Association, Nurses Advisory Board, 2017- present
- ASCO Cancer.Net Advisory Panel, Melanoma, 2016 – present
- Society for Immunotherapy of Cancer, 2017-present